Results 21 to 30 of about 48,908 (228)

Adjunctive rifampin for the treatment of Staphylococcus aureus bacteremia with deep infections: A meta-analysis.

PLoS ONE, 2020
BACKGROUND:Staphylococcus aureus (S. aureus) bacteremia (SAB) has high morbidity and mortality, with the development of methicillin-resistant S. aureus (MRSA) and the recognized shortcomings of vancomycin, its management is becoming more complicated ...
Huan Ma, Jie Cheng, Lengyue Peng, Yawen Gao, Guangli Zhang, Zhengxiu Luo   +5 more
doaj   +1 more source

Rifampin- and Multidrug-Resistant Tuberculosis in Russian Civilians and Prison Inmates: Dominance of the Beijing Strain Family

Emerging Infectious Diseases, 2002
Consecutive patient cultures (140) of Mycobacteriium tuberculosis were collected from five Russian civilian and prison tuberculosis laboratories and analyzed for rifampin (rpoB) and isoniazid resistance (inhA, katG, ahpC); transmission of Beijing family ...
Francis Drobniewski, Yanina Balabanova, Michael Ruddy, Laura Weldon, Katya Jeltkova, Timothy Brown, Nadezdna Malomanova, Elvira Elizarova, Alexander Melentyey, Ebgeny Mutovkin, Svetlana Zhakharova, Ivan Fedorin   +11 more
doaj   +1 more source

A literature review of liver function test elevations in rifampin drug–drug interaction studies

Clinical and Translational Science, 2022
Although rifampin drug–drug interaction (DDI) studies are routinely conducted, there have been instances of liver function test (LFT) elevations, warranting further evaluation.
Sherry M. Ibrahim, Yazdi K. Pithavala, Manoli Vourvahis, Joseph Chen   +3 more
doaj   +1 more source

Staphylococcal response to daptomycin in implant-associated infections [PDF]

, 2011
The use of medical devices carries the risk of infection. Due to the development of multi-resistant bacteria, missing microcirculation, and biofilm embedded bacteria these implant-associated infections are difficult to treat.
John, Anne-Kathrin
core   +1 more source

Malabsorption of Rifampin and Isoniazid in HIV-Infected Patients With and Without Tuberculosis [PDF]

, 2004
The absorption of rifampin, isoniazid, and D-xylose in patients with human immunodeficiency virus (HIV) infection and diarrhea, in patients with HIV infection and tuberculosis (TB), in patients with pulmonary TB alone, and in healthy subjects was ...
Gurumurthy, Prema, Sekar, L., Venkatesan, P, Krishnarajasekhar, O R, Krishnarajasekhar, O. R., Padmapriyadarshini, C, Venkatesan, P., Hemanth Kumar, A K, Padmapriyadarsini, C., Hemanth Kumar, A. K., Paramesh, P., Paramesh, P, Rajasekaran, S., Ramachandran, Geetha, Sekar, L, Swaminathan, Soumya, Kumar, S, Kumar, S., Rajasekaran, S   +18 more
core   +1 more source

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor

Scientific Reports, 2022
Milvexian (BMS-986177/JNJ-70033093) is a potent, oral small molecule that inhibits the active form of factor XI with high affinity and selectivity.
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J. Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy   +8 more
doaj   +1 more source

Influence of Rifampin Therapy on Serum Bactericidal Activity in the Presence of Cloxacillin and Vancomycin

Canadian Journal of Infectious Diseases, 1990
In this study the effect of rifampin on serum inhibitory and serum bactericidal titres was examined. Sera were prepared from pooled human serum to contain vancomycin (10 mg/L), cloxacillin (5 mg/L) or rifampin (1 mg/L), and the combinations cloxacillin ...
Andrew MR Mackenzie, Noni E MacDonald
doaj   +1 more source

Myelosuppression Rates with Administration of Nafcillin with and without Rifampin in Pediatric Patients

Pediatric Reports, 2022
Myelosuppression, a potential adverse reaction of nafcillin and rifampin, is rarely documented in pediatric populations. The objective of this study is to describe the incidence of myelosuppression in pediatric patients receiving nafcillin or a ...
Jolly Kuriakose, Michelle Kaplansky, Caroline M. Sierra   +2 more
doaj   +1 more source

Implant Removal in the Management of Prosthetic Joint Infection by Staphylococcus aureus: Outcome and Predictors of Failure in a Large Retrospective Multicenter Study

Antibiotics, 2021
Objectives: To compare the characteristics and outcomes of cases with acute prosthetic joint infection (PJI; early post-surgical or hematogenous) by Staphylococcus aureus managed with implant removal (IRm) or debridement and retention (DAIR).
Joan Gómez-Junyent, Jaime Lora-Tamayo, Josu Baraia-Etxaburu, Mar Sánchez-Somolinos, Jose Antonio Iribarren, Dolors Rodriguez-Pardo, Julia Praena-Segovia, Luisa Sorlí, Alberto Bahamonde, Melchor Riera, Alicia Rico, Mª Dolores del Toro, Laura Morata, Javier Cobo, Luis Falgueras, Natividad Benito, Elena Muñez, Alfredo Jover-Sáenz, Carles Pigrau, Javier Ariza, Oscar Murillo   +20 more
doaj   +1 more source

Biofilm Time-Kill Curves to Assess the Bactericidal Activity of Daptomycin Combinations against Biofilm-Producing Vancomycin-Resistant Enterococcus faecium and faecalis

Antibiotics, 2021
Introduction: E. faecium and E. faecalis are responsible for 13.9% of hospital-acquired infections with frequent resistance to vancomycin (82.6% of E. faecium, 9.5% of E. faecalis).
Katie E. Barber, Zade Shammout, Jordan R. Smith, Razieh Kebriaei, Taylor Morrisette, Michael J. Rybak   +5 more
doaj   +1 more source